Interview with Denis Remenyako, General Director of FC Grand Capital, on Russia24 channel

FC Grand Capital continues its steady climb up the RBC TOP 500 ranking. The company moved up another 50 positions, increasing revenue and profits by a third on the previous year. This is the fifth consecutive year the rankings have been released; the rating's objectives are to identify Russia's largest companies, identifying their affiliation by industry and identifying trends in economic processes taking place in sectors of the Russian economy. The main indicator for ranking companies is their revenues net of VAT, excise duties and export duties. In the RBC 500 ranking, only Russian companies are given numbered positions.

The III Stolypin Forum: 'The Immune System of the World Economy' featured a panel discussion on 'The Trust Environment as an Engine of Health Industry Development', supported by Grand Capital Group. The discussion presented the experience of European countries and analysed Russian practices in the field of tax administration, including the experience of tax incentives for companies in the pharmaceutical sector to increase private investment in innovation. European and Russian pharmaceutical executives took part in the discussion:
 Jacek Wisniewski, Director of Sales and Distribution, Polpharma Group (Poland);
 Alisa Vitalyevna Dzhangiryants, Director of Market Access and Pricing, Bristol-Myers Squibb LLC (Russia);
 Eder Stefan, Executive Vice-President of STADA AG for the Russia and CIS region;
 Yelena Vasilyevna Tkachenko, General Director of Avexima JSC;
 Frederik Paulsen, Chairman of the Board of Directors of Ferring Pharmaceuticals;
 Yekaterina Ryabova, PwC Partner, Head of the Tax Function Effectiveness Practice.
The discussion was moderated by Denis Remenyako, General Director of FC Grand Capital.
Recording of the discussion at the link: https://stolypinforum.ru/sreda-doveria-ru